Company news
Compass Therapeutics, Inc. news in 2021
Compass Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Compass Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference
November 21, 2021
Compass Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 11, 2021
Compass Therapeutics Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market
October 31, 2021
Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market
October 31, 2021
Compass Reports the Advancement of CTX-009, a Bispecific Antibody, to Phase 2a Development in Patients with Biliary Tract Cancers (BTC), and the Clearance of a Key Clinical Hurdle
October 31, 2021
CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 7, 2021
Compass Therapeutics and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 30, 2021
Compass Therapeutics to Present at the Citi 16th Annual Biopharma Virtual Conference
August 12, 2021
Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.
May 12, 2021
Compass Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 4, 2021
Compass Therapeutics to Commence Trading on the OTCQB Venture Market Under the Symbol “CMPX”
March 3, 2021
Compass Therapeutics Announces Participation in March 2021 Investor Conferences
March 3, 2021